Alzamend Neuro, Inc(ALZN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALZN Alzamend Neuro, Inc

Not Yet Opened 03-16 16:00:00 EDT

2.10

+0.06

+2.94%

盘后2.12

+0.02+0.95%

19:53 EDT

High2.36	Low2.05	Vol828.53K
Open2.25	D1 Closing2.04	Amplitude15.02%
Mkt Cap7.98M	Tradable Cap7.95M	Total Shares3.80M
T/O1.84M	T/O Rate21.89%	Tradable Shares3.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALZN","market":"US","secType":"STK","nameCN":"Alzamend Neuro, Inc","latestPrice":2.1,"timestamp":1773691200000,"preClose":2.04,"halted":0,"volume":828530,"hourTrading":{"tag":"盘后","latestPrice":2.12,"preClose":2.1,"latestTime":"19:53 EDT","volume":19159,"amount":41217.3309,"timestamp":1773705235730,"change":0.02,"changeRate":0.009524,"amplitude":0.066667},"delay":0,"changeRate":0.029411764705882377,"floatShares":3784500,"shares":3801600,"eps":-2.99368,"marketStatus":"Not Yet Opened","change":0.06,"latestTime":"03-16 16:00:00 EDT","open":2.245,"high":2.3565,"low":2.05,"amount":1836006.572224,"amplitude":0.150245,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.99368,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773734400000},"marketStatusCode":0,"adr":0,"listingDate":1623729600000,"exchange":"NASDAQ","adjPreClose":2.04,"preHourTrading":{"tag":"盘前","latestPrice":2.23,"preClose":2.04,"latestTime":"09:29 EDT","volume":48803,"amount":108218.21723030001,"timestamp":1773667799131,"change":0.19,"changeRate":0.093137,"amplitude":0.147059},"postHourTrading":{"tag":"盘后","latestPrice":2.12,"preClose":2.1,"latestTime":"19:53 EDT","volume":19159,"amount":41217.3309,"timestamp":1773705235730,"change":0.02,"changeRate":0.009524,"amplitude":0.066667},"volumeRatio":12.341694,"impliedVol":1.3738,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ALZN","defaultTab":"news","newsList":[{"id":"2619682514","title":"BRIEF-Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 \"Lithium In Brain\" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2619682514","media":"Reuters","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619682514?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:17","pubTimestamp":1773663452,"startTime":"0","endTime":"0","summary":"BRIEF-Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 \"Lithium In Brain\" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General HospitalMarch 16 (Reuters) - Alza","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA6G460F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ALZN","BK4139"],"gpt_icon":0},{"id":"2618971658","title":"Alzamend Neuro Inc reports results for the quarter ended January 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2618971658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618971658?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:22","pubTimestamp":1773267763,"startTime":"0","endTime":"0","summary":"Alzamend Neuro Inc reports results for the quarter ended January 31 - Earnings SummaryAlzamend Neuro Inc ALZN.OQ reported a quarterly adjusted loss of 58 cents per share for the quarter ended January ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL8N3ZZ337:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN","BK4139","BK4539"],"gpt_icon":0},{"id":"2618768239","title":"Alzamend Neuro Q3 net loss widens 112% to USD 2.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618768239","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618768239?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:53","pubTimestamp":1773262397,"startTime":"0","endTime":"0","summary":"Alzamend Neuro reported a net loss of USD 2.2 million for Q3 ended Jan. 31, with a loss from operations of USD 2.2 million. Research and development expense rose 189% to USD 1.28 million, driven by higher clinical trial fees related to the AL001 Phase IIB healthy-subject study conducted with Massachusetts General Hospital. General and administrative expense increased 56% to USD 0.92 million, mainly due to higher legal fees tied to litigation following termination of the ALZN002 clinical trial. The company reported no revenue for the quarter and said it expects to report topline data in Q1 2026 from the completed clinical portion of its Phase II study of AL001 in healthy subjects.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL14GJr6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN","BK4139","BK4539"],"gpt_icon":0},{"id":"2617537376","title":"Alzamend Neuro Establishes ATM Equity Offering Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2617537376","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617537376?lang=en_us&edition=fundamental","pubTime":"2026-03-07 06:16","pubTimestamp":1772835390,"startTime":"0","endTime":"0","summary":"Alzamend Neuro ( ($ALZN) ) has issued an update. On March 6, 2026, Alzamend Neuro, Inc. entered into an at-the-market issuance sales agreement with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alzamend-neuro-establishes-atm-equity-offering-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alzamend-neuro-establishes-atm-equity-offering-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","BK4539","EQR","BK4215","ALZN","BK4585"],"gpt_icon":0},{"id":"2617653857","title":"BRIEF-Alzamend Neuro Inc - Enters ATM Sales Agreement To Sell Up To $3.0 Million In Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617653857","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617653857?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:51","pubTimestamp":1772833899,"startTime":"0","endTime":"0","summary":"BRIEF-Alzamend Neuro Inc - Enters ATM Sales Agreement To Sell Up To $3.0 Million In Common Stock - SEC FilingMarch 6  - Alzamend Neuro Inc ALZN.O:ALZAMEND NEURO INC - ENTERS ATM SALES AGREEMENT TO SELL UP TO $3.0 MILLION IN COMMON STOCK - SEC FILINGFurther company coverage: ALZN.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nFWN3ZU1EC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN","BK4539","BK4139"],"gpt_icon":0},{"id":"2617658470","title":"Alzamend Neuro Inc - Enters Atm Sales Agreement to Sell up to $3.0 Mln in Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617658470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617658470?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:44","pubTimestamp":1772833456,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nFWN3ZU1EC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALZN","BK4539","BK4139"],"gpt_icon":0},{"id":"2617588846","title":"Alzamend Neuro Inc  expected to post a loss of $1.92 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2617588846","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617588846?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:09","pubTimestamp":1772831345,"startTime":"0","endTime":"0","summary":"Alzamend Neuro Inc  expected to post a loss of $1.92 a share - Earnings Preview Alzamend Neuro Inc ALZN.OQ ALZN.O is expected to  show no change in quarterly revenue when it reports  results on March ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL8N3ZU2LX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALZN","BK4539"],"gpt_icon":0},{"id":"2610354669","title":"Alzamend Neuro Inc. Announces Date for 2026 Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2610354669","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610354669?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:31","pubTimestamp":1770672710,"startTime":"0","endTime":"0","summary":"Alzamend Neuro Inc. will hold its 2026 Annual Meeting of Stockholders on April 17, 2026. During the meeting, shareholders will vote on several key proposals, including the election of seven directors, the ratification of the appointment of Haskell & White LLP as the company’s independent registered public accounting firm for the fiscal year ending April 30, 2026, a non-binding advisory vote on compensation paid to named executive officers, approval of the company’s 2025 Equity Incentive Plan, approval of equity issuances to directors and executive officers, and approval of an amendment to the company’s Certificate of Incorporation to effect a reverse stock split of the company’s common stock.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL7JxBgM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN","BK4539","BK4139"],"gpt_icon":0},{"id":"2595274807","title":"Director Milton C. Ault III Reports Sale of Alzamend Neuro Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595274807","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595274807?lang=en_us&edition=fundamental","pubTime":"2025-12-31 06:54","pubTimestamp":1767135285,"startTime":"0","endTime":"0","summary":"Milton C. Ault, III, Director of Alzamend Neuro Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL63bg1r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Milton C. Ault III Reports Sale of Alzamend Neuro Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALZN","BK4539"],"gpt_icon":0},{"id":"2593443453","title":"Director William B. Horne Reports Disposal of Alzamend Neuro Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593443453","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593443453?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:30","pubTimestamp":1766525453,"startTime":"0","endTime":"0","summary":"William B. Horne, Director of Alzamend Neuro Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL8D2xM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Director William B. Horne Reports Disposal of Alzamend Neuro Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ALZN"],"gpt_icon":0},{"id":"2593948225","title":"Alzamend Neuro Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2593948225","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593948225?lang=en_us&edition=fundamental","pubTime":"2025-12-22 20:24","pubTimestamp":1766406240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALZN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 22, 2025 07:24 ET (12:24 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN"],"gpt_icon":0},{"id":"2593510240","title":"U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2593510240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593510240?lang=en_us&edition=fundamental","pubTime":"2025-12-22 15:49","pubTimestamp":1766389793,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Comerica, Heico, WalmartDec 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Comerica, Heico and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL4N3XS0F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","AXP","GOOGL","COF","HEI","ANF","LU0187121727.USD","DKNG","T","LU1951200564.SGD","CINF","CYTK","LU0052756011.USD","CWAN","DRI","CCL","FLUT","AZZ","CAG","CRSR","CUBE","BK4516","FOLD","ALZN","GAP","CMA","BOW","BMBL","FITB","IE00B19Z8X17.USD","LU0323591593.USD","FBLG","APRE","LU2275660780.HKD","BMRN","FISV","LU1116320737.USD","LEU","BKSY","EOSE","AIG","LU2242649171.HKD","CFG","AFL","FRT","ALLY","AKTX","LU0689472784.USD","ELF","ASB"],"gpt_icon":1},{"id":"2590327303","title":"Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2590327303","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590327303?lang=en_us&edition=fundamental","pubTime":"2025-12-10 06:37","pubTimestamp":1765319864,"startTime":"0","endTime":"0","summary":"Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(1.96) by 84.65 percent. This is a 91.69 percent increase over losses of $(3.61) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/12/49294170/alzamend-neuro-q2-eps-0-30-beats-1-96-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN"],"gpt_icon":0},{"id":"2584920227","title":"BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet","url":"https://stock-news.laohu8.com/highlight/detail?id=2584920227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584920227?lang=en_us&edition=fundamental","pubTime":"2025-11-20 02:59","pubTimestamp":1763578756,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, AlphabetEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL6N3WV0MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVL","ON","DLB","FCX","XOM","MSTR","NNOX","CDE","ALZN","WDC","RIOT","PRAX","DOW","COP","GEV","NEM","NVDA","ZION","VTVT","OLMA","SION","STX","TGT","CSIQ","GOOGL","PLUG","VVV","GLAD","GLBE","CEVA","RAPP","NNE","KZIA","H","ONCY","PPL","RDW","LZB","SHBI","AGIO","ACHR","COIN","OKLO","OWL","OXY","DY","LOW","CVX","SNDK","SCCO"],"gpt_icon":0},{"id":"2584294473","title":"BRIEF-Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Ii Clinical Trial Of Al001 \"Lithium In Brain\" Study Conducted At Massachusetts General Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584294473","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584294473?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:58","pubTimestamp":1763560714,"startTime":"0","endTime":"0","summary":"BRIEF-Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Ii Clinical Trial Of Al001 \"Lithium In Brain\" Study Conducted At Massachusetts General HospitalAlzamend Neuro Inc ALZN.O:ALZAMEND","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA3SP9BV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN","BK4539","BK4139"],"gpt_icon":1},{"id":"2584886944","title":"BUZZ-Alzamend rises after completing mid-stage brain lithium study","url":"https://stock-news.laohu8.com/highlight/detail?id=2584886944","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584886944?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:34","pubTimestamp":1763559274,"startTime":"0","endTime":"0","summary":"BUZZ-Alzamend rises after completing mid-stage brain lithium study** Shares of clinical-stage drug developer Alzamend Neuro ALZN.O rise 5.74% to $2.58 premarket** Co says it finished the clinical portion of a mid-stage trial of AL001, a lithium-based therapy for Alzheimer's and mood disorders** Study compared AL001 with marketed lithium carbonate to measure lithium levels in blood and brain using advanced imaging, co says** Co says goal is to deliver lithium more effectively to the brain while reducing systemic side effects and avoiding frequent blood tests** ALZN expects to release the main results in early 2026** Up to last close, stock down ~77% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALZN","BK4539"],"gpt_icon":0},{"id":"2584949428","title":"Alzamend Neuro Announces Completion of Clinical Portion of Phase Ii Clinical Trial of Al001 \"Lithium in Brain\" Study Conducted at Massachusetts General Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949428","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949428?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:00","pubTimestamp":1763557203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA3SP9BV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALZN","BK4539","BK4139"],"gpt_icon":0},{"id":"2584789946","title":"EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2584789946","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584789946?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:30","pubTimestamp":1763555400,"startTime":"0","endTime":"0","summary":"Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/19/Dementia-In-Senior-People--Memory-Loss--.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/19/Dementia-In-Senior-People--Memory-Loss--.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48946190/exclusive-alzamend-wraps-clinical-phase-of-al001-study-in-healthy-participants","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48946190/exclusive-alzamend-wraps-clinical-phase-of-al001-study-in-healthy-participants","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["ALZN","BK4139","BK4539"],"gpt_icon":0},{"id":"2584697639","title":"Alzamend Neuro Mourns Loss of Director Andrew Woo","url":"https://stock-news.laohu8.com/highlight/detail?id=2584697639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584697639?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:06","pubTimestamp":1763503614,"startTime":"0","endTime":"0","summary":"Alzamend Neuro ( ($ALZN) ) just unveiled an announcement. Alzamend Neuro, Inc. announced the passing of Andrew H. Woo, M.D., Ph.D., a director who ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alzamend-neuro-mourns-loss-of-director-andrew-woo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alzamend-neuro-mourns-loss-of-director-andrew-woo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALZN","BK4539","BK4139"],"gpt_icon":0},{"id":"2578540139","title":"Alzamend Neuro Director Lynne Fahey McGrath Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2578540139","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578540139?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:30","pubTimestamp":1761337848,"startTime":"0","endTime":"0","summary":"Lynne Fahey McGrath, Director at Alzamend Neuro Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDLbD7CFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ALZN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alzamend.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.2883},{"period":"3month","weight":-0.0278},{"period":"6month","weight":-0.16},{"period":"1year","weight":-0.6554},{"period":"ytd","weight":0.1538}],"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.021244},{"month":2,"riseRate":0.2,"avgChangeRate":-0.139445},{"month":3,"riseRate":0.8,"avgChangeRate":0.025355},{"month":4,"riseRate":0.25,"avgChangeRate":-0.118996},{"month":5,"riseRate":0.25,"avgChangeRate":-0.068872},{"month":6,"riseRate":0,"avgChangeRate":-0.237835},{"month":7,"riseRate":0.2,"avgChangeRate":-0.179706},{"month":8,"riseRate":0.4,"avgChangeRate":-0.193815},{"month":9,"riseRate":0.4,"avgChangeRate":-0.01602},{"month":10,"riseRate":0.2,"avgChangeRate":-0.167499},{"month":11,"riseRate":0,"avgChangeRate":-0.126469},{"month":12,"riseRate":0,"avgChangeRate":-0.232408}],"exchange":"NASDAQ","name":"Alzamend Neuro, Inc","nameEN":"Alzamend Neuro, Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alzamend Neuro, Inc(ALZN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alzamend Neuro, Inc(ALZN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alzamend Neuro, Inc,ALZN,Alzamend Neuro, Inc股票,Alzamend Neuro, Inc股票老虎,Alzamend Neuro, Inc股票老虎国际,Alzamend Neuro, Inc行情,Alzamend Neuro, Inc股票行情,Alzamend Neuro, Inc股价,Alzamend Neuro, Inc股市,Alzamend Neuro, Inc股票价格,Alzamend Neuro, Inc股票交易,Alzamend Neuro, Inc股票购买,Alzamend Neuro, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alzamend Neuro, Inc(ALZN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alzamend Neuro, Inc(ALZN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}